



ARGEN-X REACHES MILESTONE IN SIMPLE ANTIBODY™ RESEARCH AND PRODUCT DEVELOPMENT COLLABORATION WITH SHIRE

Breda, the Netherlands and Ghent, Belgium September 19, 2013 – arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody™ research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of *in vivo* proof of concept for one of the antibody discovery programs undertaken in the collaboration.

Under their February 29, 2012 agreement, the companies are collaborating to create human therapeutic antibodies against complex targets involved in severe, rare genetic diseases. Shire has an option to license the most promising antibody leads from each collaborative program for further development and commercialization worldwide, in return for milestone and royalty payments. Under the terms of the license, arGEN-X has already received technology access fees and research funding and is eligible to receive preclinical success payments.

"We are pleased with the excellent progress that has resulted from an outstanding joint effort between our teams," said Hans de Haard, PhD, Chief Scientific Officer of arGEN-X. "This collaboration milestone is testament to the superiority of our proprietary SIMPLE Antibody™ platform and reinforces our brand in the complex targets space."

_____ends_____

About arGEN-X – www.arGEN-X.com

arGEN-X is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics with highly differentiated target product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune indications, are designed to deliver tangible benefits to patients with these diseases.

arGEN-X' SIMPLE Antibody™ platform generates an unprecedented diversity of high quality human antibodies, enabling optimal product choice. SIMPLE Antibodies™ are able to address and modulate any disease target, including complex receptors and highly conserved targets often intractable with other antibody technologies. SIMPLE Antibody™ generated leads are further differentiated as products through enhancement of cell killing properties (POTELLIGENT®, licensed from BioWa Inc.) and optimization of circulation time and distribution in the body (NHance™). ArGEN-X is also developing ABDEG™ technology, to potentiate the clearance of disease-causing autoantibodies.



In January 2013, arGEN-X initiated a Phase Ib clinical trial for ARGX-110, its most advanced SIMPLE Antibody™ program modulating CD70 via a unique mode of action in hematological and virally-induced solid tumors. A Phase Ib trial for ARGX-111, a novel anti-c-Met antibody to treat diverse solid tumors, was initiated in September 2013.

The SIMPLE Antibody™ platform is covered by broad patent claims, enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions.

SIMPLE stands for **S**uperior **I**mmunodiversity with **M**inimal **P**rotein **L**ead **E**ngineering.

arGEN-X™, SIMPLE Antibody™ and NHance™ are deposited trademarks of arGEN-X BV.

For further information, please contact:

Citigate Dewe Rogerson

David Dible
Mark Swallow

T: +44 207 282 2949/2948
E: david.dible@citigatedr.co.uk
E: mark.swallow@citigatedr.co.uk

arGEN-X

Tim Van Hauwermeiren, MSc, eMBA
Chief Executive Officer

T: +31 6 122 85 257
E: tim.vh@argen-x.com

Debbie Allen, Ph.D.
Senior Director, Business Development

T: +44 7974 979479
E: dallen@argen-x.com